Nitroalkene Benzoic Acid Derivatives for ALS Neuroinflammation Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for amyotrophic lateral sclerosis (ALS) and related neurodegenerative conditions are not curative and only provide modest therapeutic effects, failing to slow or stop the progression of paralysis effectively.
Innovation Solution
The use of electrophilic nitroalkene derivatives, such as (E)-4-(2-nitrovinyl) benzoic acid, to inhibit NF-κB activation in microglia, thereby reducing neuroinflammation and slowing paralysis progression in ALS models.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If current drugs (riluzole and edaravone) are used for ALS treatment, then patient survival is extended by a few months, but the therapeutic effect remains modest and clinically irrelevant for most patients
Solution Approach 1:
The patent changes the therapeutic parameter from modest survival extension to significant survival prolongation by introducing nitroalkene derivatives that potently inhibit NF-κB activation in microglia, transforming the therapeutic outcome from clinically irrelevant to highly effective in ALS treatment
Solution Approach 2:
The patent introduces nitroalkene derivatives as intermediary compounds that specifically target and inhibit NF-κB activation in microglia, serving as a mediator between the pathological process and therapeutic intervention to achieve reliable neuroprotection
2Reliability
If NF-κB activation in microglia is inhibited using nitroalkene derivatives, then neuroinflammation is reduced and motor neuron function is preserved, but the complexity of the treatment mechanism increases
Solution Approach 1:
The patent extracts and isolates the specific pathological mechanism of NF-κB activation in microglia as the primary target for intervention, separating this key pathogenic pathway from the complex network of inflammatory processes to enable focused and effective therapeutic action
Solution Approach 2:
The patent replaces complex mechanical or physiological interventions with a chemically-based solution using nitroalkene derivatives that directly inhibit NF-κB activation through molecular interaction, simplifying the treatment approach while maintaining high efficacy
3Productivity
If microglial proliferation and activation are allowed to proceed, then the natural disease progression occurs, but neurotoxicity increases and motor neurons are damaged
Solution Approach 1:
The patent converts the harmful neurotoxic potential of activated microglia into a beneficial therapeutic opportunity by specifically inhibiting NF-κB activation, thereby transforming microglia from harmful agents into protected elements that no longer contribute to neuronal damage
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The nitroalkene derivatives significantly prolong survival and preserve motor neuron function in ALS models by downregulating NF-κB activation and reducing microglial-mediated neurotoxicity, offering a more effective treatment approach than existing drugs.
Implementation Method 1
The compounds of the invention are electrophilic in nature and react with nucleophiles through a Michael addition reaction
Data Source
AI summary
This invention relates to the use of nitroalkene derivatives for the treatment of neurodegenerative conditions in mammals in which neuroinflammation is a contributing factor, such as in amyotrophic lateral sclerosis (ALS).